NCT05148091View on ClinicalTrials.gov

The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

478

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

August 4, 2023

Study Completion Date

August 4, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

SCTV01C

A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants

OTHER

Adjuvant

SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial

OTHER

Saline

Saline is used as the other control in the trial

Trial Locations (5)

100034

Peking University First Hospital, Beijing

100176

Beijing Tongren Hospital, CMU, Beijing

230001

Anhui Provincial Hospital, Hefei

410005

Hunan Provincial Center for Disease Control And Prevention, Changsha

050011

PetroChina Central Hospital, Langfang

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY

NCT05148091 - The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults | Biotech Hunter | Biotech Hunter